Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association CongressGlobeNewsWire • 06/12/25
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual MeetingGlobeNewsWire • 06/02/25
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AMLGlobeNewsWire • 06/01/25
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual MeetingGlobeNewsWire • 05/22/25
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) CongressGlobeNewsWire • 05/14/25
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GISTGlobeNewsWire • 04/28/25
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDAGlobeNewsWire • 04/08/25
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual MeetingGlobeNewsWire • 03/26/25
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An OpportunitySeeking Alpha • 03/04/25
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial DesignsGlobeNewsWire • 02/05/25
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual MeetingGlobeNewsWire • 12/09/24